Country: Canada
Language: English
Source: Health Canada
DAPAGLIFLOZIN
TEVA CANADA LIMITED
A10BK01
DAPAGLIFLOZIN
5MG
TABLET
DAPAGLIFLOZIN 5MG
ORAL
100
Prescription
Active ingredient group (AIG) number: 0156370001; AHFS:
APPROVED
2023-05-15
_Teva-Dapagliflozin Page 1 of 72_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEVA-DAPAGLIFLOZIN dapagliflozin tablets Tablets, 5 mg and 10 mg, Oral ATC Code: A10BK01 Sodium-glucose co-transporter 2 (SGLT2) inhibitors Teva Canada Limited 30 Novopharm Court Toronto, Ontario M1B 2K9 Canada Date of Initial Authorization: DEC 21, 2021 Submission Control No: 246884 _Teva-Dapagliflozin Page 2 of 72_ RECENT MAJOR LABEL CHANGES NOT APPLICABLE. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ....................................................................................................... 2 TABLE OF CONTENTS ......................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................................. 4 1 INDICATIONS ........................................................................................................................ 4 1.1 Pediatrics ............................................................................................................................ 4 1.2 Geriatrics ............................................................................................................................ 4 2 CONTRAINDICATIONS ........................................................................................................... 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ...................................................................... 5 4 DOSAGE AND ADMINISTRATION ........................................................................................... 5 4.1 Dosing Considerations ........................................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment .................................................................. 5 4.5 Missed Dose .................................. Read the complete document